BenevolentAI said it will still develop its internally discovered drugs, but will now seek partners for them earlier in their development. Going forward, BenevolentAI will focus on making its AI technologies available to support the drug R&D efforts of its partners.
The post AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots appeared first on MedCity News.
